Lynda Charters
Natamycin still the best bet for fungal keratitis
A recent study sponsored by the National Eye Institute (NEI) of the optimal treatments for fungal keratitis showed that topical natamycin is still the mainstay of treatment. Adding oral voriconazole to the treatment regimen also may be beneficial to treat patients with Fusarium species.
Intracanalicular insert soothes ocular itching in allergic conjunctivitis
A phase III study of dexamethasone insert, 0.4 mg (Dextenza, Ocular Therapeutix) found that the sustained-release intracanalicular insert is safe, effective, and well tolerated for treating ocular itching associated with allergic conjunctivitis.
Tapping gene therapy potential for inherited retinal diseases
Tapping gene therapy potential for inherited retinal diseases
The gene therapy technology already exists to treat most inherited retinal disease. The current challenge is to drive down the costs of implementing the technology.
Patching after unilateral cataract: Less may be more
Gradual reductions in the amount of patching from 3 to 4 hours at 1 year of age showed significantly better outcomes in children who undergo unilateral congenital cataract surgery.
Uncovering diagnostic clues, insights in pediatric neurodegenerative cases
Recognition of the neuro-ophthalmic findings in pediatric neurodegenerative diseases may yield insight into the diagnosis of these diseases. Ophthalmic clues should not be overlooked.
Novel glaucoma treatments factor in scleral behavior
Innovations in sustained-drug delivery and neuroprotection are bringing glaucoma specialists one step closer to additional therapeutic options.
Limiting inflammation may decrease nerve damage, preserve cell function
Evidence supports the involvement of an important pathway in retinal ganglion cell dysfunction and death in traumatic optic neuropathy.
Role of dysfunctional lens in refractive lens exchange
Staging patients based on their ocular pathologies using the most advanced diagnostic tools can result in excellent image quality by precisely establishing the need for lens- or corneal-based procedures.
New molecule enhances effect of anti-VEGF therapy for DME
Activation of Tie2–as a result of subcutaneous administration of AKB-9778 (Aerpio Therapeutics) in combination with an anti-vascular endothelial growth factor (anti-VEGF) therapy–enhances the effect of an anti-VEGF drug on diabetic macular edema (DME).
Dropless cataract surgery effective choice without compliance issues
Dropless prophylaxis in patients scheduled to undergo cataract surgery seems to be more practical than and as efficacious as the standard of care for use in this patient population.
var script= ' ';